Acrivon Retained Earnings from 2010 to 2024

ACRV Stock

7.58 0.06 0.80%

Acrivon Therapeutics, Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Acrivon Therapeutics, Common retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2010-12-31

Previous Quarter

-116.4 M

Current Value

-110.6 M

Quarterly Volatility

37.4 M

Credit Downgrade

Yuan Drop

Covid

Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 22.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.94. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.

Check out the analysis of Acrivon Therapeutics, Correlation against competitors.

Latest Acrivon Therapeutics,'s Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Acrivon Therapeutics, Common over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Acrivon Therapeutics,'s Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (116.42 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Acrivon Retained Earnings Regression Statistics

	Arithmetic Mean	(26,850,533)
	Coefficient Of Variation	(139.16)
	Mean Deviation	26,999,920
	Median	(8,622,000)
	Standard Deviation	37,366,017
	Sample Variance	1396.2T
	Range	107.8M
	R-Value	(0.71)
	Mean Square Error	744.2T
	R-Squared	0.51
	Significance	0
	Slope	(5,938,032)
	Total Sum of Squares	19547.1T

Acrivon Retained Earnings History

	2024	-110.6 M
	2023	-116.4 M
	2022	-56 M
	2021	-24.9 M

Other Fundumenentals of Acrivon Therapeutics,

Retained Earnings Total Equity

Acrivon Therapeutics, Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse
Total Assets		0.87	0.84	-0.68	-0.81	0.69	0.39	0.87	-0.53	0.99	0.9	0.99	0.96	0.9	0.78	0.7	-0.53
Total Stockholder Equity	0.87		0.92	-0.23	-0.78	0.63	-0.11	1.0	-0.48	0.82	0.98	0.81	0.91	0.98	0.36	0.73	-0.48
Net Tangible Assets	0.84	0.92		-0.3	-0.95	0.87	-0.04	0.92	-0.79	0.83	0.95	0.82	0.92	0.95	0.44	0.89	-0.79
Net Debt	-0.68	-0.23	-0.3		0.44	-0.43	-0.94	-0.23	0.29	-0.74	-0.34	-0.75	-0.56	-0.34	-0.99	-0.32	0.29
Retained Earnings	-0.81	-0.78	-0.95	0.44		-0.97	-0.14	-0.78	0.88	-0.85	-0.88	-0.83	-0.91	-0.88	-0.57	-0.96	0.88
Accounts Payable	0.69	0.63	0.87	-0.43	-0.97		0.18	0.63	-0.94	0.75	0.75	0.73	0.81	0.75	0.55	0.95	-0.94
Total Liab	0.39	-0.11	-0.04	-0.94	-0.14	0.18		-0.11	-0.09	0.46	0.0	0.47	0.24	0.0	0.88	0.02	-0.09
Net Invested Capital	0.87	1.0	0.92	-0.23	-0.78	0.63	-0.11		-0.48	0.82	0.98	0.81	0.91	0.98	0.36	0.73	-0.48
Short Long Term Debt	-0.53	-0.48	-0.79	0.29	0.88	-0.94	-0.09	-0.48		-0.57	-0.57	-0.55	-0.61	-0.57	-0.41	-0.81	1.0
Total Current Assets	0.99	0.82	0.83	-0.74	-0.85	0.75	0.46	0.82	-0.57		0.88	1.0	0.97	0.88	0.83	0.75	-0.57
Capital Stock	0.9	0.98	0.95	-0.34	-0.88	0.75	0.0	0.98	-0.57	0.88		0.87	0.97	1.0	0.47	0.85	-0.57
Net Working Capital	0.99	0.81	0.82	-0.75	-0.83	0.73	0.47	0.81	-0.55	1.0	0.87		0.96	0.87	0.83	0.73	-0.55
Short Term Debt	0.96	0.91	0.92	-0.56	-0.91	0.81	0.24	0.91	-0.61	0.97	0.97	0.96		0.97	0.67	0.86	-0.61
Common Stock	0.9	0.98	0.95	-0.34	-0.88	0.75	0.0	0.98	-0.57	0.88	1.0	0.87	0.97		0.47	0.85	-0.57
Property Plant Equipment	0.78	0.36	0.44	-0.99	-0.57	0.55	0.88	0.36	-0.41	0.83	0.47	0.83	0.67	0.47		0.43	-0.41
Current Deferred Revenue	0.7	0.73	0.89	-0.32	-0.96	0.95	0.02	0.73	-0.81	0.75	0.85	0.73	0.86	0.85	0.43		-0.81
Capital Surpluse	-0.53	-0.48	-0.79	0.29	0.88	-0.94	-0.09	-0.48	1.0	-0.57	-0.57	-0.55	-0.61	-0.57	-0.41	-0.81

Click cells to compare fundamentals

About Acrivon Therapeutics, Financial Statements

Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-116.4 M	-110.6 M
Retained Earnings Total Equity	-50.4 M	-53 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC